MET and cancer: In our efforts to uncover the molecular mechanisms underlying the MET-mediated protection from NMDAR2B cleavage, we performed proteomic array screening, simultaneously examining 84 human cancer-related proteins, including proteases and protease inhibitors frequently dysregulated in cancer (Table S1).